Glaukos Corporation
GKOS
Ранг среди акций
#2022
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Цена акции
$174.03
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$10.26B
Изменение (1 день)
4.34%
Изменение (1 год)
129.35%
Страна
US
Торговля Glaukos Corporation (GKOS)
Категория
Healthcare
Выручка компании Glaukos Corporation (GKOS)
Выручка на Jun 2026 TTM: $612.84M
Согласно последним финансовым отчетам Glaukos Corporation, текущая выручка компании (TTM) составляет $612.84M. В 2023 году компания получила выручку $314.71M больше, чем выручке в 2022 году, которая составила $282.86M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Glaukos Corporation с 2012 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $612.84M | 59.81% |
| 2024 | $383.48M | 21.85% |
| 2023 | $314.71M | 11.26% |
| 2022 | $282.86M | -3.79% |
| 2021 | $294.01M | 30.70% |
| 2020 | $224.96M | -5.07% |
| 2019 | $236.98M | 30.73% |
| 2018 | $181.28M | 13.83% |
| 2017 | $159.25M | 39.21% |
| 2016 | $114.40M | 59.55% |
| 2015 | $71.70M | 57.28% |
| 2014 | $45.59M | 117.64% |
| 2013 | $20.95M | 762.33% |
| 2012 | $2.43M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $46.59B | 7,501.51% |
US
|
|
| $35.48B | 5,690.10% |
IE
|
|
| $25.84B | 4,115.95% |
US
|
|
| $21.00B | 3,326.02% |
US
|
|
| - | - |
DE
|
